Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000647 · ClinicalTrials.gov registry record · NA
An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT00000647: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000647 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000647, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
To restore immunologic function and virus-free state in HIV-infected patients. Based on previous studies showing temporary improvement in immune function in HIV-infected patients using peripheral lymphocyte transfers and bone marrow transplantation, and based on studies documenting the antiretroviral effects of zidovudine (AZT) and interferon-alfa (IFN-A) as well as the preliminary test tube and patient studies suggesting anti-HIV effects of recombinant CD4-IgG, we propose to treat HIV-infected patients using combination antiretroviral therapy with transplantation of bone marrow and peripheral lymphocytes from previously immunized donors in an attempt to restore immunologic function and a virus-free state.
Interventions
- DRUG Zidovudine
- DRUG Interferon alfa-n1
- DRUG CD4-IgG
- PROCEDURE Peripheral lymphocyte infusion
- PROCEDURE Bone marrow transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Est. Completion | 1994-12 |
| Phase | NA |
What the finished NCT00000647 record still lists
NCT00000647 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 5 interventions - of which Zidovudine is the first listed.
NCT00000647 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000647 about?
NCT00000647 is a clinical study titled "An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection". To restore immunologic function and virus-free state in HIV-infected patients. Based on previous studies showing temporary improvement in immune function in HIV-infected patients using peripheral lymphocyte transfers and bone marrow transplantation, and based on studies documenting the antiretrovira...
What is the current status of trial NCT00000647?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. Estimated completion is 1994-12.
What interventions are being tested in trial NCT00000647?
The interventions under investigation include: Zidovudine (DRUG), Interferon alfa-n1 (DRUG), CD4-IgG (DRUG), Peripheral lymphocyte infusion (PROCEDURE), Bone marrow transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00000647?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00000647's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08